[go: up one dir, main page]

WO2018097629A1 - Préparation à libération prolongée de varénicline et procédé pour sa production - Google Patents

Préparation à libération prolongée de varénicline et procédé pour sa production Download PDF

Info

Publication number
WO2018097629A1
WO2018097629A1 PCT/KR2017/013447 KR2017013447W WO2018097629A1 WO 2018097629 A1 WO2018097629 A1 WO 2018097629A1 KR 2017013447 W KR2017013447 W KR 2017013447W WO 2018097629 A1 WO2018097629 A1 WO 2018097629A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
sustained release
weight
hydroxypropylmethylcellulose
carbomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/013447
Other languages
English (en)
Korean (ko)
Inventor
김관영
조경아
신호철
김남호
유헌승
박여진
이규호
사준호
곽용규
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Chemicals Co Ltd
Original Assignee
SK Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Chemicals Co Ltd filed Critical SK Chemicals Co Ltd
Publication of WO2018097629A1 publication Critical patent/WO2018097629A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a pharmaceutical composition containing varenicline or a pharmaceutically acceptable salt thereof by using a matrix-type sustained release drug delivery system, and an oral sustained-release preparation using the same. More specifically, the present invention is a pharmaceutical composition containing varenicline or a pharmaceutically acceptable salt thereof, and oral using the same, which shows continuous absorption when administered to the human body and improves the patient's compliance with the daily dose. It relates to a sustained release formulation.
  • Varenicline acts as a partial agonist on ⁇ 4 ⁇ 2 neuronal nicotinic acetylcholine receptors, blocking the binding of nicotine to the receptor and at the same time significantly lower receptor activity than nicotine. It suppresses excessive dopamine release by nicotine and releases a small amount of dopamine, which can be used as a smoking cessation aid by relieving nicotine craving and withdrawal symptoms during smoking cessation.
  • the drug is administered via dose titration, which is first given 0.5 mg of varenicline once a day for 3 days. After that, take 0.5 mg twice a day from 4 to 7 days. After week 12, the dose of 1.0 mg twice daily with varenicline is used to maintain effective blood levels and alleviate withdrawal symptoms.
  • the present invention provides a pharmaceutical composition capable of improving drug compliance with a once-a-day administration by delaying the release of a sustained-release preparation containing varenicline or a pharmaceutically acceptable salt thereof, and an oral sustained-release preparation using the same. To provide.
  • the present invention provides a sustained release matrix system comprising varenicline or a pharmaceutically acceptable salt thereof and a matrix polymer.
  • the present invention provides a pharmaceutical formulation improved orally administered by oral administration once a day through a formulation comprising varenicline or a pharmaceutically acceptable salt thereof and a matrix polymer.
  • the present invention provides a method of using the pharmaceutical formulation to reduce nicotine poisoning in a subject or to help stop or reduce tobacco use.
  • the method comprises administering to the subject an oral administration of the drug in an amount of varenicline effective to reduce nicotine poisoning, or to help stop or reduce tobacco use.
  • Varenicline has a structure such as the following formula.
  • varenicline shall include a compound having a structure such as the above formula, a pharmaceutically acceptable salt, solvate and / or hydrate, racemate, polymorph or prodrug thereof.
  • the active ingredient used herein may be not only varenicline having a structure of the above formula, but also pharmaceutically acceptable salts, solvates and / or hydrates, racemates, polymorphs thereof of varenicline. Or prodrugs.
  • “pharmaceutically acceptable salts” may refer to nontoxic acid addition salts derived from inorganic and organic acids. Suitable salt derivatives include halides, thiocyanates, sulfates, bisulfates, sulfites, bisulfites, arylsulfonates, alkylsulfates, phosphonates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, als Decanoate, cycloalkylalkanoate, arylalkanoate, adipate, alginate, aspartate, benzoate, fumarate, glucoheptanoate, glycerophosphate, lactate, maleate, nicotinate, oxalate Salicylate, Palmitate, pectinate, picrate, pivalate, succinate, tartrate, citrate, camphorrate, camphorsulfonate, digluconate, trifluoroacetate, and the like
  • the term “effective amount” means an amount determined in consideration of such points as is known in the art to help reduce nicotine poisoning in an individual or to stop or reduce the use of tobacco, wherein this is Measurable alleviation, lack of dependency on nicotine-containing compounds, such as indicating improvement, including but not limited to faster recovery, amelioration or elimination of symptoms, or reduction of complications, necessarily in the treated patient , Lack of desire for nicotine-containing compounds, or other measures known and appropriate to those skilled in the medical arts.
  • the pharmaceutical composition of varenicline may exert an effect such as treatment, improvement, recovery, alleviation, etc. on the subject, preferably once daily administration.
  • mgA means mg of active drug based on the free base form of the drug, more preferably about 0.2 to 5 mgA / day, most preferably about 0.3 to 4 It may be administered at a dose in the range of mgA / day, most preferably at a dose in the range of 0.5 to 2 mgA / day.
  • changes in this dosage must be made depending on the weight and condition of the subject to be treated.
  • dosage levels below the lower limit of the aforementioned range may be more appropriate, while in other cases even larger doses may be used without causing any adverse side effects.
  • the present invention is to configure and provide a sustained release matrix system using a matrix polymer.
  • the matrix for application to varenicline or a pharmaceutically acceptable salt thereof may be greatly influenced by the low dosage of the varenicline drug due to the high dosage of polymers and other excipients in the formulation.
  • varenicline is a drug that has a very high solubility in water, so if the matrix is eroded or swelled in a short time, and the surface area is increased, the drug is not delayed and released quickly. Found. In order to solve this problem, it is necessary to select the type and ratio of the polymer that is not eroded and at the same time, it is necessary to use a polymer having a low degree of swelling.
  • the matrix polymer according to the present invention is a polymer capable of forming a matrix system in a formulation, and includes hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (hydroxyethyl cellulose, HEC, carbomer, xanthan gum, alginic acid, pregelatinized starch, carboxymethylcellulose, polyethylene oxide, propylene glycol alginate ), Methacrylic acid-acrylic acid ethyl polymer, dimethyl methacrylate methyl methacrylate (dimethyl methyl ethyl methacrylate, methyl methacrylate copolymer (Eudragit E)), methacrylic acid meth-methacrylate trimethylammonium ethyl copolymer ( Eudragit RS), methacrylic acid-acrylic acid ethyl ester copolymer, dimethylamino Ethyl methacrylate-methacrylic acid ester cop
  • the formulation has a particularly good sustained release profile when hydroxypropylmethylcellulose (HPMC) and carbomer are used together as matrix polymer.
  • HPMC hydroxypropylmethylcellulose
  • the inventors of the present invention first confirmed that varenicline or its pharmaceutically acceptable salts had different sustained-release profiles depending on the type, composition ratio, content, etc. of the matrix polymer.
  • the formulation of the present invention may comprise any one or more selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylcellulose, carbomer, xanthan gum, alginic acid, and gelatinized starch as the matrix polymer. Hydroxypropylmethylcellulose, hydroxypropylcellulose, carbomer, xanthan gum, or mixtures thereof, more preferably hydroxypropylmethylcellulose, carbomer, or mixtures thereof.
  • the formulation of the present invention comprises hydroxypropylmethylcellulose (HPMC), carbomer or a mixture thereof as a matrix polymer
  • HPMC hydroxypropylmethylcellulose
  • carbomer carbomer or a mixture thereof as a matrix polymer
  • an object of the present invention is used when a mixture of HPMC and carbomer is used together. It may be most desirable to achieve.
  • the mixing ratio of HPMC and carbomer is preferably a weight ratio of HPMC and carbomer is 1: 0.5 to 1.5, preferably 1: 0.8-1.3, more preferably 1: 0.9-1.2, even more preferably 1: It may be a weight ratio of 1.
  • the matrix polymer in a formulation comprising varenicline or a pharmaceutically acceptable salt thereof, may include 15 to 35 wt% of the total weight of the formulation, and HPMC and carbomer may be included as the matrix polymer.
  • Formulations in which the weight ratio of HPMC to carbomer is comprised between 1: 0.5 and 1.5 may have an excellent sustained release dissolution profile. Specifically, it may take about 60 minutes to achieve 10 to 50% release, and about 2 to 16 hours to release more than 90% of the drug without sharply raising blood levels. Preferably eluted at 10 to 50% in 1 hour, less than 80% in 2 hours, 90% or more in 16 hours.
  • the matrix polymer is 500 mPaS to 400,000 mPaS, preferably 1,000 to 380,000 mPaS, and preferably 3,000 to 38, when dissolved at 2% by weight in purified water at room temperature 20, according to a process oral viscosity measurement method such as NF / EP / JP. It may have a viscosity of 350,000 mPaS, more preferably 3,500 to 300,000 mPaS, and may be used by appropriately adjusting the viscosity or mixing two or more different polymers within the above range according to the desired drug release rate. Viscosity may be appropriately changed depending on the content of the matrix polymer.
  • the matrix polymer included in the sustained release formulation of the present invention may have the following viscosity.
  • the matrix polymer may be included in the range of 3 to 75% by weight, more preferably 5 to 60% by weight, even more preferably 10 to 45% by weight, even more preferably 15 to 35% by weight, based on the total weight of the formulation. have.
  • the formulation of the present invention may further comprise a swelling control polymer.
  • the swelling control polymer has a low hydrophilicity and thus does not gel when used alone, so its matrix retention effect and sustained release effect are inferior, but it is added to the matrix polymers listed above to prevent erosion of the matrix formed by the matrix polymer, thereby promoting a synergistic and sudden release of the sustained effect. Suppress
  • the swelling control polymers include polyvinyl acetate and polyvinylacetate / polyvinylpyrrolidone mixtures (e.g. Kollidon SR®), polyvinylpyrrolidone and polyvinylpyrrolidone vinylacetate copolymers ( Polyvinylpryrroldidone-vinylacetae copolymer, copovidone), crospovidone, ethyl cellulose (EC), hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate And the like, but are not limited thereto, and preferably, polyvinylacetate and polyvinylacetate / polyvinylpyrrolidone mixtures, polyvinylpyrrolidone, and the like to prevent rapid drug release of matrix systems comprising varenicline.
  • Polyvinylpyrrolidone vinyl acetate ball There are copolymers such as may be selected.
  • the swelling control polymer may include 1 to 20% by weight, preferably 2 to 15% by weight, more preferably 3 to 10% by weight relative to the total weight of the formulation in order for the formulation of the present invention to have sustained release properties.
  • Diluents may be included in the preparation of the sustained release formulation of the present invention in view of maintaining the structure of the sustained release matrix.
  • the diluent may include microcrystalline cellulose, calcium dihydrogen phosphate, starch, mannitol, lactose and the like, preferably microcrystalline cellulose may be used for the purposes of the present invention.
  • the diluent may be included in the range of 20 to 90% by weight, preferably 30 to 85% by weight, more preferably 40 to 80% by weight relative to the total weight of the formulation for the purposes of the present invention.
  • One embodiment of the present invention provides a sustained release oral preparation comprising varenicline or a pharmaceutically acceptable salt thereof, preferably (a) varenicline or a pharmaceutically acceptable salt thereof, (b A) 5 to 60% by weight of the matrix polymer, and (c) 20 to 80% by weight of the total weight of the formulation.
  • the formulation may comprise 0.1 to 10% by weight of varenicline or a pharmaceutically acceptable salt thereof relative to the total weight of the formulation, and the varenicline or a pharmaceutically acceptable salt thereof is preferably tartrate varenyl Varenicline tartrate, varenicline free base, varenicline salicylate, varenicline oxalate or mixtures thereof may be used and more preferably Varenicline free base can be used.
  • the oral sustained release preparation of the present invention comprises (a) 0.1 to 10% by weight of varenicline or a pharmaceutically acceptable salt thereof, (b) hydroxypropylmethylcellulose, hydroxypropyl, relative to the total weight of the preparation. 3 to 75% by weight of one or two or more matrix polymers selected from the group consisting of cellulose, carbomer, xanthan gum, alginic acid, gelatinized starch or mixtures thereof, and (c) 20 to 90% by weight of microcrystalline cellulose. can do.
  • the oral sustained-release preparation of the present invention comprises (a) 0.2 to 5% by weight of varenicline or a pharmaceutically acceptable salt thereof, (b) hydroxypropylmethylcellulose, carbomer or their Oral sustained release of the sustained release matrix system containing 5 to 60% by weight of any one matrix polymer selected from the group consisting of (c) 30 to 85% by weight of microcrystalline cellulose, and orally administered once daily Formulations may be provided.
  • the oral sustained release preparation of the invention comprises (a) 0.1 to 2.5% by weight of varenicline or a pharmaceutically acceptable salt thereof, (b) hydroxypropyl 10 to 45% by weight of any one of the matrix polymers selected from the group consisting of methylcellulose, hydroxypropylcellulose, carbomer, xanthan gum, alginic acid, gelatinized starch or mixtures thereof, and (c) 40 to 80% by weight of microcrystalline cellulose. It may include, and can provide an oral sustained release formulation of the sustained release matrix system administered orally once a day.
  • One embodiment of the present invention comprises (a) 0.1 to 2.5% by weight of varenicline or a pharmaceutically acceptable salt thereof relative to the total weight of the formulation, and (b) hydroxypropylmethylcellulose, carbomer or mixtures thereof It can provide a sustained-release formulation containing 10 to 45% by weight relative to the total weight of the preparation, (c) once orally administered once a day containing 40 to 80% by weight of microcrystalline cellulose relative to the total weight of the preparation.
  • One embodiment of the present invention comprises (a) 0.1 to 2.5% by weight of varenicline or a pharmaceutically acceptable salt thereof relative to the total weight of the formulation, and (b) hydroxypropylmethylcellulose, carbomer or mixtures thereof 10 to 45% by weight of the total weight of the formulation, (c) 40 to 80% by weight of microcrystalline cellulose, and (d) polyvinylacetate, polyvinylacetate-polyvinylpyrrolidone, polyvinyl Any selected from the group consisting of pyrrolidone, poly (vinylpyrrolidone-vinylacetate) copolymer, crospovidone, ethylcellulose, hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose phthalate, and mixtures thereof It can provide a sustained release formulation to orally administered once a day containing 3 to 10% by weight.
  • the matrix polymer of the formulation is any one or more selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylcellulose, carbomer, xanthan gum, alginic acid, and gelatinized starch, wherein the matrix polymer is a formulation 3 to 75% by weight relative to the total weight may be included, more preferably 5 to 60% by weight may be included.
  • Matrix polymer of the formulation according to another embodiment of the present invention is at least one selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, carbomer, xanthan gum, alginic acid, and gelatinized starch, 3 to the total weight of the formulation
  • the viscosity of the polymer in 0.5% to 10% aqueous solution may be 1,000 mPaS (However, gelatinized starch may be 70 mPaS in 2% aqueous solution).
  • the formulations of the present invention may further comprise other pharmaceutically acceptable ingredients commonly used in the manufacture, in particular those commonly used in the manufacture of tablets.
  • excipients lubricants, lubricants, disintegrants, antioxidants, flavoring agents, preservatives, fragrances, sweeteners, pigments, pH adjusting agents, other additives and the like can be further included.
  • the excipient may include any one selected from lactose, starch, lactose, mannitol, kaolin inorganic salt (eg, sodium chloride), powdered sugar and powdered cellulose derivative, microcrystalline cellulose, or a mixture thereof. .
  • the lubricant may be included in an amount of 0.5 to 5% by weight based on the total weight of the formulation, and the lubricant may be used without limitation.
  • sugars such as white sugar, macion syrup, white sugar, gelatin, sugar and starch syrup, magnesium stearate, talc, colloidal silicon dioxide, and the like may be used as lubricants.
  • the lubricant may be selected from glycerol distearate and glycerol dibenate, but is not limited thereto.
  • the disintegrant may be selected from sodium carboxymethylcellulose, copovidone, and sodium starch glycorate, but is not limited thereto.
  • Preservatives and antioxidants may also contain, for example, ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and citric acid, chelating reagents such as ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid It may include.
  • ascorbic acid cysteine hydrochloride
  • sodium bisulfate sodium metabisulfite
  • sodium metabisulfite sodium sulfite and citric acid
  • chelating reagents such as ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid It may include.
  • EDTA ethylenediamine tetraacetic acid
  • sorbitol tartaric acid
  • phosphoric acid phosphoric acid
  • the formulation of the oral preparation of the present invention may be prepared in the form of granules, ellipsoids, matrix multiparticulates, and the like, and may have a formulation of tablets, granules, and hard capsules.
  • Varenicline or a pharmaceutically acceptable salt is included in the sustained release matrix, which may be compressed into tablets or encapsulation.
  • Oral formulations of the present invention may optionally include other pharmaceutically acceptable ingredients (eg, diluents, binders, colorants, lubricants, etc.).
  • sustained release preparation of the present invention for once-daily administration, characterized by a sustained-release matrix system containing varenicline or a pharmaceutically acceptable salt thereof as an active ingredient and comprising a matrix polymer
  • sustained release formulations may be characterized by the following dissolution profiles.
  • a formulation comprising varenicline or a pharmaceutically acceptable salt thereof may be provided as a tablet of a sustained release matrix system, preferably comprising a matrix polymer.
  • the formulation may be provided as an oral sustained release formulation for once-daily administration, wherein the release of total varenicline or its pharmaceutically acceptable salt is 0.01 N at a rate of 100 rpm into a basket at 37 ⁇ 0.5 ° C. Under conditions of 900 ml of HCl, eluting can be eluted at 10-50% in 1 hour, less than 80% in 2 hours, and at least 90% in 16 hours.
  • the oral sustained release preparation contains barrenicline free base in an amount of 0.1 to 10% by weight based on the total weight of the preparation, and includes hydroxypropylmethylcellulose and carbomer as a matrix polymer, wherein the matrix polymer is the total weight of the preparation. 10 to 45% by weight of the hydroxypropylmethylcellulose and carbomer, the mixing ratio of hydroxypropylmethylcellulose: carbomer mass ratio of 1: 0.2 to 1.5, microcrystalline cellulose contained in the formulation is a formulation 40 to 80% by weight based on the total weight may be included.
  • the drug dissolution profile and the pharmacokinetics of the formulation were checked to determine the effect on the expression of the effect of the drug (vareniclin or its pharmaceutically acceptable salts) in the human body, and according to the in vitro dissolution pattern. It was confirmed that the pharmacological kinetics of reniclin or its pharmaceutically acceptable salts were varied, and showed excellent pharmacological activity and bioavailability in vivo according to the dissolution profile of the present invention.
  • Oral sustained-release preparations containing varenicline or a pharmaceutically acceptable salt thereof according to the present invention may control the rate of drug release, exhibit sustained absorption when administered to the human body, and are administered once daily. Improve patient compliance.
  • the formulation of the present invention can reduce side effects caused by rapid blood concentration rise.
  • FIG. 9 shows the elution pattern of Test Example 8.
  • Sustained-release matrix tablets containing varenicline were prepared according to the composition tables described in Tables 2 and 3 below.
  • Varenicline tartaric acid, microcrystalline cellulose, hydroxypropylmethylcellulose, and hard silicic anhydride were filtered through a No. 30 sieve and mixed. Thereafter, magnesium stearate was added, mixed, and tableted.
  • sustained-release matrix tablets containing varenicline were prepared.
  • Varenicline tartaric acid, microcrystalline cellulose, hydroxypropyl cellulose, and hard silicic anhydride were filtered through a No. 30 sieve and mixed. Thereafter, magnesium stearate was added, mixed, and tableted.
  • sustained-release matrix tablets containing varenicline were prepared.
  • Varenicline tartaric acid, microcrystalline cellulose, hydroxyethyl cellulose and hard silicic anhydride were filtered through a No. 30 sieve and mixed. Thereafter, magnesium stearate was added, mixed, and tableted.
  • Sustained-release matrix tablets containing varenicline were prepared according to the composition table described in Table 6 below.
  • Varenicline tartaric acid, microcrystalline cellulose, matrix polymer, and hard silicic anhydride were filtered through a No. 30 sieve and mixed. Thereafter, magnesium stearate was added and mixed, followed by compression.
  • Sustained-release matrix tablets containing varenicline were prepared according to the composition table described in Table 7 below.
  • Varenicline, microcrystalline cellulose, carbomer, and hard silicic anhydride were filtered through a No. 30 sieve and mixed. Thereafter, magnesium stearate was added and mixed, followed by compression.
  • Sustained-release matrix tablets containing varenicline were prepared according to the composition table described in Table 8 below.
  • Varenicline, microcrystalline cellulose, gelatinized starch, and hard silicic anhydride were filtered through No. 30 sieve and mixed. Thereafter, magnesium stearate was added and mixed, followed by compression.
  • Sustained-release matrix tablets containing varenicline were prepared according to the composition table described in Table 9 below.
  • Varenicline, microcrystalline cellulose, swelling control polymer, and hard silicic anhydride were filtered through No. 30 sieve and mixed. Thereafter, magnesium stearate, a lubricant, was added, mixed, and compressed.
  • Sustained-release matrix tablets containing varenicline were prepared according to the composition table described in Table 10 below. Varenicline, microcrystalline cellulose, swelling control polymer, and hard silicic anhydride were filtered through No. 30 sieve and mixed. Thereafter, magnesium stearate was added and mixed, followed by compression.
  • Sustained-release matrix tablets containing varenicline were prepared according to the composition table described in Table 11 below. Varenicline, microcrystalline cellulose, swelling control polymer, and hard silicic anhydride were filtered through No. 30 sieve and mixed. Thereafter, magnesium stearate was added and mixed, followed by compression.
  • Sustained-release matrix tablets containing varenicline were prepared according to the composition table described in Table 12 below. Varenicline, microcrystalline cellulose, gelatinized starch, swelling control polymer, and hard silicic anhydride were filtered through No. 30 sieve and mixed. Thereafter, magnesium stearate was added and mixed, followed by compression.
  • Sustained-release matrix tablets containing varenicline or salts thereof were prepared according to the composition table described in Table 13 below. Varenicline or its salt, microcrystalline cellulose, hydroxypropylmethylcellulose, and hard silicic anhydride were filtered through a No. 30 sieve and mixed. Thereafter, magnesium stearate was added and mixed, followed by compression.
  • Sustained-release matrix tablets containing varenicline stannate were prepared according to the composition table described in Table 14 below. Varenicline stannate, microcrystalline cellulose, matrix polymer, and hard silicic anhydride were filtered through a No. 30 sieve and mixed. Thereafter, magnesium stearate was added and mixed, followed by compression.
  • Sustained-release matrix tablets containing varenicline free base were prepared according to the composition table described in Table 15 below.
  • Varenicline, microcrystalline cellulose, matrix polymer, and hard silicic anhydride were filtered through a No. 30 sieve and mixed. Thereafter, magnesium stearate was added and mixed, followed by compression.
  • Example 1 was eluted by the KEPCO Tenth Amendment Dissolution Test.
  • the elution method was carried out using the basket method, the stirring speed was 100rpm, the elution temperature at 37 ⁇ 0.5 °C.
  • the eluate was carried out in 900 ml of 0.01 N HCl.
  • Analytical conditions were evaluated by evaluating the concentration of varenicline using HPLC to filter the solution obtained in the above dissolution test with a 0.45 ⁇ m membrane filter.
  • Example 2 Example 3 and Example 4 were eluted by the KEPCO 10th Dissolution Dissolution Test.
  • the elution method was carried out using the basket method, the stirring speed was 100rpm, the elution temperature at 37 ⁇ 0.5 °C.
  • the eluate was carried out in 900 ml of 0.01 N HCl. Dissolution test results are shown in Table 18 below and FIGS. 2-4.
  • the dissolution test of Examples 5 and 6 was carried out according to the KEPCO Tenth Amendment Dissolution Test Method.
  • the elution method was a paddle method, the stirring speed was 100rpm, the elution temperature was carried out at 37 ⁇ 0.5 °C. Tablets were evaluated by placing them in a sinker. The eluate was carried out in 900 ml of 0.01 N HCl. Dissolution test results are shown in Table 19 and FIG. 5.
  • the comparative example 1 was eluted by the KEPCO 10th Dissolution Dissolution Test.
  • the elution method was carried out using the basket method, the stirring speed was 100rpm, the elution temperature at 37 ⁇ 0.5 °C.
  • the eluate was carried out in 900 ml of 0.01 N HCl. Dissolution test results are shown in Table 20 and FIG. 6.
  • the comparative example 2 and the comparative example 3 were eluted by the pharmacopeia 10th revision dissolution test method.
  • the elution method was a paddle method, the stirring speed was 100rpm, the elution temperature was carried out at 37 ⁇ 0.5 °C. Tablets were evaluated by placing them in a sinker. The eluate was carried out in 900 ml of 0.01 N HCl. Dissolution test results are shown in Table 21 and FIG. 7.
  • ethyl cellulose had no sustained release effect. Specifically, high molecular weight ethylcellulose showed no rapid erosion of the matrix but very fast drug release.
  • Kollidon SR ® a mixture of polyvinylacetate and polyvinylpyrrolidone, had no complete erosion when used alone, but had no sustained release at 30% and almost 90% at 45%. Use alone was not suitable. Due to this property that prevents swelling and prevents erosion of the matrix, it seems that the synergistic effect of the sustained release can be expected by using the matrix polymer together with the ratio selection.
  • the comparative example 1 and the comparative example 3 were eluted by the pharmacopeia tenth revision dissolution test method.
  • the elution method was carried out using the basket method, the stirring speed was 100rpm, the elution temperature at 37 ⁇ 0.5 °C.
  • the eluate was carried out in 900 ml of 0.01 N HCl.
  • the dissolution test results are shown in Table 22 below.
  • Example 7 The dissolution test of Example 7 was carried out by the pharmacopeia 10th modified dissolution test method.
  • the elution method was carried out using the basket method, the stirring speed was 100rpm, the elution temperature at 37 ⁇ 0.5 °C.
  • the eluate was carried out in 900 ml of 0.01 N HCl. Dissolution test results are shown in Table 23 and FIG. 8.
  • Example 8 The dissolution test of Example 8 was performed by the Pharmacopeia Tenth Amendment Dissolution Test Method. The elution method was carried out using the basket method, the stirring speed was 100rpm, the elution temperature at 37 ⁇ 0.5 °C. The eluate was carried out in 900 ml of 0.01 N HCl.
  • hydroxypropylmethylcellulose exhibits a stable sustained release effect without change in dissolution rate when varenicline or a salt thereof is contained in a sustained-release matrix using a matrix polymer.
  • Example 9 was eluted by the KEPCO 10th Dissolution Dissolution Test.
  • the elution method was carried out using the basket method, the stirring speed was 100rpm, the elution temperature at 37 ⁇ 0.5 °C.
  • the eluate was carried out in 900 ml of 0.01 N HCl.
  • Example 10 The dissolution test of Example 10 was carried out by the pharmacopeia 10th modified dissolution test method.
  • the elution method was carried out using the basket method, the stirring speed was 100rpm, the elution temperature at 37 ⁇ 0.5 °C.
  • the eluate was carried out in 900 ml of 0.01 N HCl.
  • the sustained-release effect was exhibited without a change in the effective ingredient dissolution rate in the sustained-release matrix using a combination of 10 to 15% by weight of hydroxypropylmethylcellulose and 5 to 10% by weight of carbomer.
  • the ratio of the individual matrix polymers is relatively low (5 to 15% by weight), the desired sustained release pattern can be obtained by appropriate combination of the polymers.
  • the present invention can provide a sustained release pharmaceutical formulation comprising varenicline or a pharmaceutically acceptable salt thereof.
  • formulations of the present invention may be conveniently administered once daily.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une préparation orale à libération prolongée qui est un système à matrice à libération prolongée comprenant de la varénicline ou un sel pharmaceutiquement acceptable et un polymère matriciel correspondants. La présente invention augmente l'observance aux médicaments par une administration une fois par jour et permet d'obtenir une préparation à libération prolongée présentant des effets secondaires réduits.
PCT/KR2017/013447 2016-11-24 2017-11-23 Préparation à libération prolongée de varénicline et procédé pour sa production Ceased WO2018097629A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0157714 2016-11-24
KR20160157714 2016-11-24

Publications (1)

Publication Number Publication Date
WO2018097629A1 true WO2018097629A1 (fr) 2018-05-31

Family

ID=62195988

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/013447 Ceased WO2018097629A1 (fr) 2016-11-24 2017-11-23 Préparation à libération prolongée de varénicline et procédé pour sa production

Country Status (2)

Country Link
KR (3) KR20180058644A (fr)
WO (1) WO2018097629A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109432022A (zh) * 2018-12-10 2019-03-08 江苏豪森药业集团有限公司 一种含酒石酸伐尼克兰的药物组合物及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200034293A (ko) 2018-09-21 2020-03-31 한미약품 주식회사 제어 방출용 바레니클린 제제
KR102235848B1 (ko) 2019-11-20 2021-04-05 충북대학교 산학협력단 바레니클린 또는 이의 약학적으로 허용가능한 염의 지연 방출용 정제
KR20230068877A (ko) * 2021-11-11 2023-05-18 주식회사 아울바이오 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물
KR20240115109A (ko) * 2023-01-18 2024-07-25 주식회사 아울바이오 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235850A1 (en) * 2003-05-20 2004-11-25 Pfizer Inc Pharmaceutical compositions of varenicline
WO2009027786A2 (fr) * 2007-08-29 2009-03-05 Pfizer Inc. Formes posologiques matricielles de varénicline
WO2009034431A2 (fr) * 2007-09-10 2009-03-19 Pfizer Inc. Formes posologiques à libération contrôlée de la varenicline
JP2011504490A (ja) * 2007-11-26 2011-02-10 ニューロデルム リミテッド ニコチン作動薬を含む組成物及びそれを用いる方法
KR20130106456A (ko) * 2011-04-29 2013-09-30 한국유나이티드제약 주식회사 약물 방출제어용 조성물
KR20160052473A (ko) * 2016-03-07 2016-05-12 에스케이케미칼주식회사 친수성서방폴리머의 매트릭스를 이용한 은행잎 추출물의 약학조성물 및 이를 이용한 경구용 서방성 제제

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235850A1 (en) * 2003-05-20 2004-11-25 Pfizer Inc Pharmaceutical compositions of varenicline
WO2009027786A2 (fr) * 2007-08-29 2009-03-05 Pfizer Inc. Formes posologiques matricielles de varénicline
WO2009034431A2 (fr) * 2007-09-10 2009-03-19 Pfizer Inc. Formes posologiques à libération contrôlée de la varenicline
JP2011504490A (ja) * 2007-11-26 2011-02-10 ニューロデルム リミテッド ニコチン作動薬を含む組成物及びそれを用いる方法
KR20130106456A (ko) * 2011-04-29 2013-09-30 한국유나이티드제약 주식회사 약물 방출제어용 조성물
KR20160052473A (ko) * 2016-03-07 2016-05-12 에스케이케미칼주식회사 친수성서방폴리머의 매트릭스를 이용한 은행잎 추출물의 약학조성물 및 이를 이용한 경구용 서방성 제제

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109432022A (zh) * 2018-12-10 2019-03-08 江苏豪森药业集团有限公司 一种含酒石酸伐尼克兰的药物组合物及其制备方法
CN109432022B (zh) * 2018-12-10 2021-07-06 江苏豪森药业集团有限公司 一种含酒石酸伐尼克兰的药物组合物及其制备方法

Also Published As

Publication number Publication date
KR20190059868A (ko) 2019-05-31
KR20180058644A (ko) 2018-06-01
KR20180127951A (ko) 2018-11-30
KR102479497B1 (ko) 2022-12-20

Similar Documents

Publication Publication Date Title
WO2018097629A1 (fr) Préparation à libération prolongée de varénicline et procédé pour sa production
WO2020040438A1 (fr) Préparation pharmaceutique ayant d'excellentes propriétés de dissolution, contenant de l'ésoméprazole et du bicarbonate de sodium
WO2017119801A1 (fr) Préparation pharmaceutique à usage oral et goût masqué contenant de la varénicline ou un sel pharmaceutiquement acceptable de celle-ci
WO2018111002A1 (fr) Comprimé à désintégration orale comprenant un composé de carbamate
WO2020045940A1 (fr) Composition pharmaceutique comprenant un agent antiplaquettaire et un inhibiteur de sécrétion d'acide gastrique
WO2011152652A2 (fr) Préparation d'acéclofénac à libération lente présentant un effet clinique pharmacologique optimal lorsqu'elle est administrée une fois par jour
WO2020017808A1 (fr) Comprimé à désintégration orale contenant de la nalfuron
WO2016036093A1 (fr) Film dispersible oral de tadalafil et son procédé de préparation
WO2017146286A1 (fr) Composition pharmaceutique à base d'extrait de feuille de ginkgo biloba utilisant une matrice de polymère hydrophile pour libération prolongée, et préparation à libération prolongée utilisant cette dernière
WO2017073897A1 (fr) Composition pharmaceutique comprenant de la metformine et de la lobéglitazone
WO2018062685A1 (fr) Composite formé d'une seule couche, comprenant du candésartan et de l'amlodipine
WO2019245150A1 (fr) Composition pharmaceutique comprenant du cilostazol et un médicament à base de statine
WO2016013795A1 (fr) Preparation a liberation prolongee
WO2021167364A1 (fr) Composition pharmaceutique comprenant de l'ésoméprazole et du bicarbonate de sodium présentant d'excellentes propriétés de libération
WO2015012633A1 (fr) Formulation complexe contenant de la metformine à libération prolongée et un inhibiteur de la hmg-coa réductase à libération immédiate
WO2021125824A1 (fr) Formulation pharmaceutique comprenant de la cibenzoline ou un sel de celle-ci
WO2012077968A2 (fr) Formulation complexe contenant de l'hydrochlorure de lercanidipine et du valsartan et son procédé de préparation
WO2019182321A1 (fr) Formulation de béthanéchol à libération prolongée et procédé de préparation de celle-ci
WO2023132699A1 (fr) Comprimé à libération prolongée de carvédilol à conformité améliorée par réduction de la taille de comprimé à l'aide d'une technologie de comprimé à faible excipient ilet (innovation à faible excipient)
WO2018062941A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une démence et d'un dysfonctionnement cognitif, contenant du donépézil ou un sel de qualité pharmaceutique de celui-ci et de la mémantine ou un sel de qualité pharmaceutique de celle-ci, et son procédé de préparation
WO2013157840A1 (fr) Composition composite présentant une stabilité améliorée et contenant de l'amlodipine et du rozaltan
WO2010008224A2 (fr) Comprimés d’amlodipine à dissolution rapide à stabilité améliorée et leur procédé de fabrication
WO2024063537A1 (fr) Composition pharmaceutique comprenant du sel de calcium sacubitrilㆍvalsartan
WO2017155350A1 (fr) Composition pharmaceutique pour administration par voie orale comprenant du (±)-2-[2- (3-carboxypropionyloxy)-3-diméthylaminopropoxy]-3'-méthoxybibenzyle ou des sels de celui-ci
WO2019199132A1 (fr) Composition de comprimé oral de lénalidomide dans diverses quantités

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17874308

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17874308

Country of ref document: EP

Kind code of ref document: A1